


Antibody fragments & alternative binding proteins





Extended plasma half-life

- Expanded hydrodynamic volume leading to extended circulation time
- Reduced injection frequencies



Efficient & cheap production

- Genetic fusion: high yield, homogenous product & reduced cost
- Compatible with various industry standard expression systems



Biodegradable PEG alternative

- PAS overcomes PEG hypersensitivity
- No organ accummulation during chronic treatment



PAS + binding protein enable:

- Long-acting antagonists without Fc effector functions
- Smart antibody drug conjugates (ADCs)
- T-cell engagers
- Bi-/Multispecifics

Related Publications:



Deuschle F.C. et al. (2020) Development of a high affinity Anticalin® directed against human CD98hc for theranostic applications. Theranostics 10, 2172-2187.



Brandl F. et al. (2020) Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life. J. Control Release 327, 86-197.



Aghaabdollahian S. et al. (2019) Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology. Sci. Rep. 9, 2978.



Griffiths K. et al. (2019) Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4. MAbs 11, 1331-1340.



Längin M. et al. (2018) Consistent success in life-supporting porcine cardiac xenotransplantation. Nature 564, 430-433.

Partnering contact:

XL-protein GmbH Claus Schalper Lise-Meitner-Str. 30 85354 Freising Germany

Phone: +49 (0) 8161 53730-90 Fax: +49 (0) 8161 53730-99 E-mail: bd@xl-protein.com

Web: www.xl-protein.com